Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Interferon (IFN) is a treatment option for both mycosis fungoides (MF) and hepatitis C virus (HCV) infection. Chemotherapy and anti-HCV treatment are generally not administered concurrently for fear of overlapping side effects.
Herein, we report on a subset of patients who received IFN-containing therapy for MF and HCV infection simultaneously. We aimed to evaluate whether concomitant treatment for MF and HCV is effective and well tolerated.
We reviewed the records of patients who were seen at MD Anderson Cancer Center from 2008 to 2013 with histologically confirmed MF and chronic HCV infection, and were treated with simultaneous focus on both diseases.
Six HCV-infected patients with MF received simultaneous anti-HCV and anti-MF treatment with IFN-containing therapy. Two patients achieved sustained virological response (regarded as virological cure). They both received antiviral combination therapy with ribavirin. All patients experienced some improvement of their cutaneous lesions, with two of them achieving complete MF remission. All six patients developed side effects while receiving treatment; two of them had grade 4 toxic effects requiring treatment discontinuation.
IFN-based therapy can be administered for MF and HCV infection concurrently to provide not only virological but also oncological benefits to chronically HCV-infected MF patients. However, this regimen is poorly tolerated. Further studies are warranted in this patient population, using different treatment combinations with improved efficacy, safety, and tolerability.
- Prince, HM, Whittaker, S, Hoppe, RT (2009) How I treat mycosis fungoides and Sezary syndrome. Blood 114: pp. 4337-4353 CrossRef
- Apisarnthanarax, N, Talpur, R, Duvic, M (2002) Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 3: pp. 193-215 CrossRef
- Duvic, M Cutaneous T-cell lymphomas: mycosis fungoides and Sézary syndrome. In: Younes, A, Coiffier, B eds. (2013) Lymphoma: diagnosis and treatment. Humana Press, Totowa, pp. 287-321 CrossRef
- Ghany, MG, Nelson, DR, Strader, DB, Thomas, DL, Seeff, LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: pp. 1433-1444 CrossRef
- Borchardt, RA, Torres, HA (2014) Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol 20: pp. 2771-2776 CrossRef
- Martinot-Peignoux, M, Stern, C, Maylin, S (2010) Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51: pp. 1122-1126 CrossRef
- Olsen, EA, Whittaker, S, Kim, YH (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29: pp. 2598-2607 CrossRef
- Division of AIDS table for grading the severity of adult and pediatric adverse events. Division of AIDS, Bethesda
- Gisbert, JP, Garcia-Buey, L, Arranz, R (2004) The prevalence of hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Eur J Gastroenterol Hepatol 16: pp. 135-138 CrossRef
- Lee, MH, Yang, HI, Lu, SN (2012) Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206: pp. 469-477 CrossRef
- Duberg, AS, Nordstrom, M, Torner, A (2005) Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 41: pp. 652-659 CrossRef
- Diamandidou, E, Cohen, PR, Kurzrock, R (1996) Mycosis fungoides and Sezary syndrome. Blood 88: pp. 2385-2409
- Miertusova, S, Bonin, S, Trevisan, G, Stanta, G (2004) Mycosis fungoides is not associated with hepatitis C virus infection. Br J Dermatol 151: pp. 1108-1110 CrossRef
- Vallisa, D, Bernuzzi, P, Arcaini, L (2005) Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol 23: pp. 468-473 CrossRef
- Garcia-Garcia, I, Gonzalez-Delgado, CA, Valenzuela-Silva, CM (2010) Pharmacokinetic and pharmacodynamic comparison of two “pegylated” interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol 10: pp. 15 CrossRef
- Mahale, P, Miller, ED, Blechacz, B, Herlong, HF, Davila, M, Torres, HA (2013) The effect of antiviral therapy on progression of liver disease in hepatitis C virus-infected patients with malignancies. Hepatology 58: pp. 909A
- Groopman, JE, Itri, LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: pp. 1616-1634 CrossRef
- Manns, MP, Wedemeyer, H, Cornberg, M (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55: pp. 1350-1359 CrossRef
- Khalil, F, Cualing, H, Cogburn, J, Miles, L (2007) The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study. Arch Pathol Lab Med 131: pp. 1281-1289
- American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society–USA. Initial treatment of HCV infection in patients starting treatment. Recommendations for testing, managing, and treating hepatitis C. 2014. http://www.hcvguidelines.org. Accessed 27 May 2014.
- Ferenci, P, Bernstein, D, Lalezari, J (2014) ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370: pp. 1983-1992 CrossRef
- Sulkowski, MS, Gardiner, DF, Rodriguez-Torres, M (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370: pp. 211-221 CrossRef
- Torres, HA, Mahale, P, Raad, II, Kontoyannis, DP (2013) Hepatitis C virus infection in patients with cancer: a single-institution experience in 642 patients. Hepatology 58: pp. 1290A
- Makdisi, J, Friedman, A (2013) Myocosis fungoides—an update on a non-mycotic disease. J Drugs Dermatol 12: pp. 825-831
- Yanagi, T, Shimizu, T, Ujiie, H (2006) Peginterferon alfa-2b for mycosis fungoides. Arch Dermatol 142: pp. 649-651 CrossRef
- Lange, CM, Jacobson, IM, Rice, CM, Zeuzem, S (2014) Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 6: pp. 4-15 CrossRef
- Gaetano, JN, Reau, N (2013) Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep 15: pp. 305 CrossRef
- Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series
American Journal of Clinical Dermatology
Volume 15, Issue 5 , pp 451-456
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Unit 1460, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
- 2. Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA